Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from________ to ________.

Commission File Number: 001-31573

Medifast, Inc.

(Exact name of registrant as specified in its charter)


Delaware						13-3714405
(State or other jurisdiction of incorporation or organization)						(I.R.S. Employer Identification No.)

100 International Drive

Baltimore, Maryland 21202

Telephone Number: (410) 581-8042

(Address of Principal Executive Offices, Zip Code and Telephone Number, Including Area Code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, par value $0.001 per share

MED

New York Stock Exchange

Indicate by checkmark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by checkmark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o No x

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

The number of shares of the registrant’s common stock outstanding at October 23, 2023 was 10,892,602.

Table of Contents

Medifast, Inc. and Subsidiaries

Index


Part 1 – Financial Information



Item 1 – Financial Statements


Condensed Consolidated Statements of Income (unaudited) for the Three and Nine Months Ended September 30 , 2023 and 2022			2

Condensed Consolidated Statements of Comprehensive Income (unaudited) for the Three and Nine Months Ended September 30 , 2023 and 2022			3

Condensed Consolidated Balance Sheets (unaudited) as of September 30 , 2023 and December 31, 2022			4

Condensed Consolidated Statements of Cash Flows (unaudited) for the Nine Months Ended September 30, 2023 and 2022			5

Condensed Consolidated Statements of Changes in Stockholders’ Equity (unaudited) for the Nine Months Ended September 30, 2023 and 2022			6

Notes to Condensed Consolidated Financial Statements (unaudited)			8

Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations			15

Item 3 – Quantitative and Qualitative Disclosures about Market Risk			22

Item 4 – Controls and Procedures			23

Part II – Other Information

Item 1 – Legal Proceedings			24

Item 1A – Risk Factors			24

Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds			24

Item 6 – Exhibits			25

Table of Contents

MEDIFAST, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)

(U.S. dollars in thousands, except per share amounts & dividend data)


	Three months ended September 30,				Nine months ended September 30,
	2023		2022		2023		2022

Revenue	$	235,869	$	390,398	$	881,039	$	1,261,332
Cost of sales	58,492		107,549		246,558		354,515
Gross profit	177,377		282,849		634,481		906,817

Selling, general, and administrative	151,868		234,693		516,755		754,610

Income from operations	25,509		48,156		117,726		152,207

Other income (expense)
Interest income (expense)	1,033		(261)		1,314		(519)
Other income (expense)	7		(17)		(45)		(37)
	1,040		(278)		1,269		(556)

Income from operations before income taxes	26,549		47,878		118,995		151,651

Provision for income taxes	3,418		11,723		25,615		34,601

Net income	$	23,131	$	36,155	$	93,380	$	117,050

Earnings per share - basic	$	2.12	$	3.30	$	8.58	$	10.37

Earnings per share - diluted	$	2.12	$	3.27	$	8.55	$	10.30

Weighted average shares outstanding
Basic	10,892		10,964		10,881		11,290
Diluted	10,933		11,042		10,925		11,369

Cash dividends declared per share	$	1.65	$	1.64	$	4.95	$	4.92

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

MEDIFAST, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)

(U.S. dollars in thousands)


	Three months ended September 30,				Nine months ended September 30,
	2023		2022		2023		2022

Net income	$	23,131	$	36,155	$	93,380	$	117,050

Other comprehensive income, net of tax:
Foreign currency translation	27		123		125		300
Unrealized losses on investment securities	(9)		—		(9)		(21)
	18		123		116		279

Comprehensive income	$	23,149	$	36,278	$	93,496	$	117,329

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

MEDIFAST, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)

(U.S. dollars in thousands, except par value)


	September 30, 2023		December 31, 2022

ASSETS
Current Assets
Cash and cash equivalents	$	112,751	$	87,691
Investment securities	45,009		—
Inventories	58,227		118,856

Prepaid expenses and other current assets	8,289		16,237
Total current assets	224,276		222,784

Property, plant and equipment - net of accumulated depreciation	53,484		57,185
Right-of-use assets	15,681		18,460
Other assets	15,753		12,456
Deferred tax assets	10,825		5,328


TOTAL ASSETS	$	320,019	$	316,213

LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts payable and accrued expenses	$	103,223	$	134,690
Income taxes payable	1,417		428
Current lease obligations	5,472		5,776
Total current liabilities	110,112		140,894

Lease obligations, net of current lease obligations	16,872		20,275


Total liabilities	126,984		161,169

Stockholders' Equity
Common stock, par value $0.001 per share: 20,000 shares authorized;
10,892 and 10,928 issued and 10,892 and 10,873 outstanding
at September 30, 2023 and December 31, 2022, respectively	11		11
Additional paid-in capital	24,107		21,555
Accumulated other comprehensive income	141		24
Retained earnings	168,776		139,852
Less: treasury stock at cost, 0 and 54 shares at September 30, 2023 and December 31, 2022, respectively	—		(6,398)
Total stockholders' equity	193,035		155,044

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	320,019	$	316,213

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

MEDIFAST, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(U.S. dollar in thousands)


	Nine months ended September 30,
	2023		2022

Operating Activities
Net income	$	93,380	$	117,050
Adjustments to reconcile net income to cash provided by operating activities
Depreciation and amortization	9,754		8,026
Non-cash lease expense	3,532		4,740
Share-based compensation	5,795		8,103

Loss on sale or disposal of property, plant and equipment	622		—
Amortization of premium on investment securities	—		14
Deferred income taxes	(5,497)		(1,746)

Change in operating assets and liabilities:
Inventories	60,629		34,764

Prepaid expenses and other current assets	7,948		1,889
Other assets	(4,674)		(8,545)
Accounts payable and accrued expenses	(35,343)		(22,259)
Income taxes payable	989		795
Net cash flow provided by operating activities	137,135		142,831

Investing Activities
Sale and maturities of investment securities	—		5,267
Purchase of investment securities	(44,779)		—
Purchase of property and equipment	(5,537)		(7,617)
Net cash flow used in investing activities	(50,316)		(2,350)

Financing Activities


Options exercised by directors	105		—
Net shares repurchased for employee taxes	(3,348)		(1,504)
Cash dividends paid to stockholders	(55,039)		(53,698)
Stock repurchases	(3,602)		(120,048)
Net cash flow used in financing activities	(61,884)		(175,250)

Foreign currency impact	125		296

Increase (Decrease) in cash and cash equivalents	25,060		(34,473)
Cash and cash equivalents - beginning of the period	87,691		104,183
Cash and cash equivalents - end of period	$	112,751	$	69,710

Supplemental disclosure of cash flow information:
Income taxes paid	$	30,169	$	33,906
Dividends declared included in accounts payable	$	19,184	$	19,395

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

MEDIFAST, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (UNAUDITED)

(U.S. dollars in thousands)


	Nine months ended September 30, 2023
	Number of Shares Issued	Common Stock		Additional Paid-In Capital		Accumulated Other Comprehensive Income		Retained Earnings		Treasury Stock		Total

Balance, December 31, 2022	10,928	$	11	$	21,555	$	24	$	139,852	$	(6,398)	$	155,044
Net income	—	—		—		—		39,968		—		39,968
Share-based compensation	69	—		606		—		—		—		606
Options exercised by directors	4	—		105		—		—		—		105
Net shares repurchased for employee taxes	(30)	—		(3,236)		—		—		—		(3,236)
Treasury stock from stock repurchases	—	—		—		—		—		(3,602)		(3,602)
Treasury stock retired from stock repurchases	(84)	—		—		—		(10,000)		10,000		—
Other comprehensive income	—	—		—		9		—		—		9
Cash dividends declared to stockholders	—	—		—		—		(17,994)		—		(17,994)

Balance, March 31, 2023	10,887	$	11	$	19,030	$	33	$	151,826	$	—	$	170,900
Net income	—	—		—		—		30,280		—		30,280
Share-based compensation	2	—		2,514		—		—		—		2,514
Net shares repurchased for employee taxes	—	—		(2)		—		—		—		(2)
Other comprehensive income	—	—		—		90		—		—		90
Cash dividends declared to stockholders	—	—		—		—		(18,221)		—		(18,221)

Balance, June 30, 2023	10,889	$	11	$	21,542	$	123	$	163,885	$	—	$	185,561
Net income	—	—		—		—		23,131		—		23,131
Share-based compensation	4	—		2,675		—		—		—		2,675
Net shares repurchased for employee taxes	(1)	—		(110)		—		—		—		(110)
Other comprehensive income	—	—		—		18		—		—		18
Cash dividends declared to stockholders	—	—		—		—		(18,240)		—		(18,240)

Balance, September 30, 2023	10,892	$	11	$	24,107	$	141	$	168,776	$	—	$	193,035

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents


	Nine months ended September 30, 2022
	Number of Shares Issued	Common Stock		Additional Paid-In Capital		Accumulated Other Comprehensive Income		Retained Earnings		Treasury Stock		Total

Balance, December 31, 2021	11,594	$	12	$	12,018	$	111	$	190,333	$	—	$	202,474
Net income	—	—		—		—		41,781		—		41,781
Share-based compensation	18	—		2,275		—		—		—		2,275
Net shares repurchased for employee taxes	(8)	—		(1,459)		—		—		—		(1,459)
Treasury stock from stock repurchases	—	—		—		—		—		(10,000)		(10,000)
Treasury stock retired from stock repurchases	(51)	—		—		—		(10,000)		10,000		—
Other comprehensive income	—	—		—		16		—		—		16
Cash dividends declared to stockholders	—	—		—		—		(19,063)		—		(19,063)

Balance, March 31, 2022	11,553	$	12	$	12,834	$	127	$	203,051	$	—	$	216,024
Net income	—	—		—		—		39,113		—		39,113
Share-based compensation	1	—		2,865		—		—		—		2,865
Net shares repurchased for employee taxes	—	—		(20)		—		—		—		(20)
Treasury stock from stock repurchases	—	—		—		—		—		(90,038)		(90,038)
Treasury stock retired from stock repurchases	(535)	(1)		—		—		(90,038)		90,038		(1)
Stock Repurchases, not yet settled	—	—		(15,679)		—		(4,331)		—		(20,010)
Other comprehensive income	—	—		—		141		—		—		141
Cash dividends declared to stockholders	—	—		—		—		(18,598)		—		(18,598)

Balance, June 30, 2022	11,019	$	11	$	—	$	268	$	129,197	$	—	$	129,476
Net income	—	—		—		—		36,155		—		36,155
Share-based compensation	1	—		2,963		—		—		—		2,963
Net shares repurchased for employee taxes	—	—		(25)		—		—		—		(25)
Treasury stock from stock repurchases	—	—		—		—		—		(20,010)		(20,010)
Treasury stock retired from stock repurchases	(91)	—		—		—		(20,010)		20,010		—
Settlement of accelerated share repurchase agreement	—	—		15,679		—		4,331		—		20,010
Other comprehensive income	—	—		—		123		—		—		123
Cash dividends declared to stockholders	—	—		—		—		(18,170)		—		(18,170)

Balance, September 30, 2022	10,929	$	11	$	18,617	$	391	$	131,503	$	—	$	150,522

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

MEDIFAST, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation - The accompanying unaudited condensed consolidated financial statements of Medifast, Inc. and its wholly-owned subsidiaries (“Medifast,” the “Company,” “we,” “us,” or “our”) included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim reporting and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and notes that are normally required by GAAP have been condensed or omitted. However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included and management believes the disclosures that are made are adequate to make the information presented not misleading. The condensed consolidated balance sheet at December 31, 2022 has been derived from the 2022 audited consolidated financial statements at that date included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (“2022 Form 10-K”).

The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of results that may be expected for the fiscal year ending December 31, 2023. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in the 2022 Form 10-K.

Presentation of Financial Statements - The unaudited condensed consolidated financial statements included herein include the accounts of the Company. All significant intercompany accounts and transactions have been eliminated.

Use of Estimates - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.

Recently Issued Accounting Pronouncements - The Company has not adopted any new accounting standards during the nine months ended September 30, 2023. There are no recently issued accounting pronouncements that are expected to have a material effect on the Company’s financial position, results of operations, cash flows, or disclosures.

2. INVENTORIES

Inventories consist principally of raw materials, packaging, non-food finished goods and finished packaged meal replacements held in the Company’s warehouses and outsourced distribution centers. Inventories are stated at the lower of cost or net realizable value, utilizing the first-in, first-out method. The cost of finished goods includes the cost of raw materials, packaging supplies, direct and indirect labor and other indirect manufacturing costs. On a quarterly basis, management reviews inventories for unsalable or obsolete inventories.

Inventories consisted of the following (in thousands):


	September 30, 2023		December 31, 2022

Raw materials	$	8,491	$	12,670
Packaging	2,269		3,611
Non-food finished goods	4,426		8,738
Finished goods	49,558		97,675
Reserve for obsolete inventory	(6,517)		(3,838)
Total	$	58,227	$	118,856

Table of Contents

3. EARNINGS PER SHARE

Basic earnings per share (“EPS”) computations are calculated utilizing the weighted average number of shares of the Company’s common stock outstanding during the periods presented. Diluted EPS is calculated utilizing the weighted average number of shares of the Company’s common stock outstanding adjusted for the effect of dilutive common stock equivalents.

The following table sets forth the computation of basic and diluted EPS (in thousands, except per share data):


	Three months ended September 30,				Nine months ended September 30,
	2023		2022		2023		2022

Numerator:
Net income	$	23,131	$	36,155	$	93,380	$	117,050

Denominator:
Weighted average shares of common stock outstanding	10,892		10,964		10,881		11,290
Effect of dilutive common stock equivalents	41		78		44		79
Weighted average shares of common stock outstanding	10,933		11,042		10,925		11,369

Earnings per share - basic	$	2.12	$	3.30	$	8.58	$	10.37

Earnings per share - diluted	$	2.12	$	3.27	$	8.55	$	10.30

The calculation of diluted EPS excluded 13 thousand and 10 thousand antidilutive restricted stock awards for the three months ended September 30, 2023 and 2022, respectively, and 15 thousand and 3 thousand antidilutive restricted stock awards for the nine months ended September 30, 2023 and 2022, respectively. EPS is computed independently for each of the periods presented above, and accordingly, the sum of the quarterly earnings per common share may not equal the year-to-date total computed.

4. SHARE-BASED COMPENSATION

Stock Options

The Company has issued non-qualified and incentive stock options to employees and non-employee directors. The fair value of these options are estimated on the date of grant using the Black-Scholes option pricing model, which requires estimates of the expected term of the option, the risk-free interest rate, the expected volatility of the price of the Company’s common stock, and dividend yield. Options outstanding as of September 30, 2023 generally vested over a period of 3 years and expire 10 years from the date of grant. The exercise price of these options ranges from $26.52 to $66.68. Due to the Company’s lack of option exercise history on the date of grant, the expected term is calculated using the simplified method defined as the midpoint between the vesting period and the contractual term of each option. The risk free interest rate is based on the U.S. Treasury yield curve in effect on the date of grant that most closely corresponds to the expected term of the option. The expected volatility is based on the historical volatility of the Company’s common stock over the period of time equivalent to the expected term for each award. The dividend yield is computed as the annualized dividend rate at the grant date divided by the strike price of the stock option. For the nine months ended September 30, 2023 and 2022, the Company did not grant stock options.

Table of Contents

The following table is a summary of our stock option activity (in thousands, except per share data):


	Nine months ended September 30,
	2023			2022
	Awards	Weighted-Average Exercise Price		Awards	Weighted-Average Exercise Price

Outstanding at beginning of period	33	$	54.98	33	$	54.98
Exercised	(4)	27.18		—	—
Outstanding at end of the period	29	$	58.65	33	$	54.98
Exercisable at end of the period	29	$	58.65	28	$	52.76

As of September 30, 2023, the weighted-average remaining contractual life for both the outstanding stock options and exercisable stock options was 3.8 years with an aggregate intrinsic value of $0.5 million. The compensation expense calculated under the fair value method for the nine months ended September 30, 2023 was less than $0.1 million and was fully recognized during the period. For the nine months ended September 30, 2023, the Company received $0.1 million in cash proceeds from the exercise of stock options. The total intrinsic value for stock options exercised during the nine months ended September 30, 2023 was $0.3 million.

Restricted Stock

The Company has issued restricted stock to employees and non-employee directors generally with vesting terms up to 5 years after the date of grant. The fair value of the restricted stock is equal to the market price of the Company’s common stock on the date of grant. Expense for restricted stock is amortized ratably over the vesting period.

The following table summarizes our restricted stock activity (in thousands, except per share data):


	Nine months ended September 30,
	2023			2022
	Shares	Weighted-Average Grant Date Fair Value		Shares	Weighted-Average Grant Date Fair Value

Outstanding at beginning of period	60	$	188.11	44	$	183.51
Granted	86	97.96		38	176.60
Vested	(25)	169.46		(19)	156.16
Forfeited	(5)	142.11		(1)	186.53
Outstanding at end of the period	116	$	127.57	62	$	187.83

The Company withheld approximately 10 thousand shares and 8 thousand shares of the Company’s common stock to cover minimum tax liability withholding obligations upon the vesting of shares of restricted stock for the nine months ended September 30, 2023 and 2022, respectively. The total fair value of restricted stock awards vested during the nine months ended September 30, 2023 and 2022 was $2.6 million and $3.4 million, respectively.

Market and Performance-based Share Awards

The Company has issued market and performance-based share awards to certain key executives who were granted deferred shares and may earn between 0% and 250% of the target number depending upon both the Company’s total stockholder return (“TSR”) and the Company’s performance against predetermined performance goals over a three-year performance period. Market and performance-based share awards that are tied to the Company’s TSR are valued using the Monte Carlo method and are recognized ratably as expense over the award’s performance period. The fair value of the performance-based share awards is equal to the market price of the Company’s common stock on the date of grant adjusted by expected level of achievement over the performance period. Expense for performance-based share awards is amortized ratably over the performance period. In the event that management determines that the Company will not reach the lower threshold of the predetermined performance goals established in the grant agreement, any previously recognized expense is reversed in the period in which such a determination is made. Management determined that the market and performance-based share awards granted in 2022 would

Table of Contents

not reach the lower threshold of the predetermined performance goal resulting in a $1.4 million decrease in the Company’s share-based compensation expense for the nine months ended September 30, 2023.

The Company withheld approximately 22 thousand shares of the Company’s common stock to cover minimum tax liability withholding obligations upon the issuance of shares of market and performance-based share awards for the nine months ended September 30, 2023. No market and performance-based share awards vested and no shares were withheld to cover minimum tax liability withholding obligations for the nine months ended September 30, 2022. The total fair value of market and performance-based share awards issued during the nine months ended September 30, 2023 and 2022 was $5.7 million and $0, respectively.

Share-based compensation expense for all types of awards granted is recorded in selling, general, and administrative expense in the accompanying Condensed Consolidated Statements of Income. The total expense during the three months ended September 30, 2023 and 2022 as follows (in thousands):


	Three months ended September 30,
	2023			2022
	Shares	Share-Based Compensation Expense		Shares	Share-Based Compensation Expense
Options and restricted stock	145	$	1,558	90	$	1,392
Market and performance-based share awards granted in 2023	47	487		—	—
Market and performance-based share awards granted in 2022	24	—		25	438
Performance-based share awards granted in 2021	14	620		15	654
Performance-based share awards granted in 2020	28	10		26	479
Total share-based compensation	258	$	2,675	156	$	2,963

The total expense during the nine months ended September 30, 2023 and 2022 as follows (in thousands):


	Nine months ended September 30,
	2023			2022
	Shares	Share-Based Compensation Expense		Shares	Share-Based Compensation Expense
Options and restricted stock	145	$	4,426	90	$	3,789
Market and performance-based share awards granted in 2023	47	1,048		—	—
Market and performance-based share awards granted in 2022	24	(1,388)		25	950
Performance-based share awards granted in 2021	14	1,600		15	1,941
Performance-based share awards granted in 2020	28	109		26	1,423
Total share-based compensation	258	$	5,795	156	$	8,103

The total income tax benefit recognized in the accompanying Condensed Consolidated Statements of Income for stock awards was $0.3 million and $0.4 million for the three months ended September 30, 2023 and 2022, respectively, and $0.4 million and $1.2 million for the nine months ended September 30, 2023 and 2022, respectively.

There was $9.3 million of total unrecognized compensation cost related to restricted stock awards as of September 30, 2023, which is expected to be recognized over a weighted-average period of 1.9 years. There was $5.1 million of unrecognized compensation costs related to the 113 thousand market and performance-based shares presented in the table above as of September 30, 2023, which is expected to be recognized over a weighted-average period of 1.8 years.

Table of Contents

5. LEASES

Operating Leases

The Company has operating leases for office and warehouse space and certain equipment. In certain of the Company’s lease agreements, the rental payments are adjusted periodically based on defined terms within the lease. The Company did not have any finance leases as of September 30, 2023 and 2022, respectively, or during the nine-month periods then ended, respectively.

The Company’s leases relating to office and warehouse space have lease terms ranging from 19 months to 122 months. The Company’s leases relating to equipment have lease terms ranging from 24 months to 203 months, with certain of them having automatic renewal clauses.

The Company’s warehouse agreements also contain non-lease components, in the form of payments towards variable logistics services and labor charges, which the Company is obligated to pay based on the services consumed by it. Such amounts are not included in the measurement of the lease liability but are recognized as expenses when they are incurred.

The operating lease expense was $1.1 million and $1.7 million for the three months ended September 30, 2023 and 2022, respectively, and $3.9 million and $5.2 million for the nine months ended September 30, 2023 and 2022, respectively.

Supplemental cash flow information related to the Company’s operating leases was as follows (in thousands):


	Nine months ended September 30,
	2023		2022

Cash paid for amounts included in the measurements of lease liabilities
Operating cash flow used in operating leases	$	4,838	$	5,413

Right-of-use assets obtained in exchange for lease obligations
Operating leases	$	753	$	103

As of September 30, 2023, the weighted average remaining lease term was 4 years, 2 months and the weighted average discount rate was 2.00%.

The following table presents the maturity of the Company’s operating lease liabilities as of September 30, 2023 (in thousands):


2023 (excluding the nine months ended September 30, 2023)	$	1,435
2024	5,955
2025	6,095
2026	4,438
2027	2,553
Thereafter	2,858
Total lease payments	$	23,334
Less: imputed interest	(990)
Total	$	22,344

Table of Contents

6. ACCUMULATED OTHER COMPREHENSIVE INCOME

The following table sets forth the components of accumulated other comprehensive income, net of tax where applicable (in thousands):


	September 30, 2023		December 31, 2022

Foreign currency translation	$	150	$	24
Unrealized net losses on investment securities	(9)		—
Accumulated other comprehensive (loss)/income	$	141	$	24

7. FINANCIAL INSTRUMENTS

Certain financial assets and liabilities are accounted for at fair value, which is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The following fair value hierarchy prioritizes the inputs used to measure fair value:

Level 1 – Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis.

Level 2 – Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies.

Level 3 – Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value from the perspective of a market participant.

The following tables present the Company’s cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands):


	September 30, 2023
	Cost		Unrealized Gains (Losses)		Accrued Interest		Estimated Fair Value		Cash & Cash Equivalents		Investment Securities

Cash	$	107,656	$	—	$	—	$	107,656	$	107,656	$	—

Level 1:
Money market accounts	5,033		—		62		5,095		5,095		—
Government & agency securities	15,200		17		28		15,245		—		15,245

	20,233		17		90		20,340		5,095		15,245

Level 2:
Corporate bonds	29,579		(26)		211		29,764		—		29,764

Total	$	157,468	$	(9)	$	301	$	157,760	$	112,751	$	45,009

Table of Contents


	December 31, 2022
	Cost		Unrealized Gains (Losses)		Accrued Interest		Estimated Fair Value		Cash & Cash Equivalents		Investment Securities

Cash	$	87,691	$	—	$	—	$	87,691	$	87,691	$	—

Level 1:
Money market accounts	—		—		—		—		—		—
Government & agency securities	—		—		—		—		—		—
	—		—		—		—		—		—




Total	$	87,691	$	—	$	—	$	87,691	$	87,691	$	—

The Company had no realized gain or loss for the three and nine months ended September 30, 2023 and 2022.

8. DEBT

Credit Agreement

On April 13, 2021, the Company and certain of its subsidiaries (collectively, the “Guarantors”) entered into a credit agreement (the “Credit Agreement”) among the Company, the Guarantors, the lenders party thereto and Citibank, N.A., in its capacity as administrative agent. On May 31, 2022, the Credit Agreement was amended to increase the borrowing capacity and convert the interest rate to be based on Secured Overnight Financing Rate (“SOFR”), from London Inter-Bank Offered Rate (LIBOR) (the “Amended Credit Agreement”). The Amended Credit Agreement provides for a $225.0 million senior secured revolving credit facility with a $20.0 million letter of credit sublimit. The Amended Credit Agreement also provides for an uncommitted incremental facility that permits the Company, subject to certain conditions, to increase the senior secured revolving credit facility by up to $100.0 million. The Amended Credit Agreement matures on April 13, 2026.

The Company’s obligations under the Amended Credit Agreement are guaranteed by the Guarantors. The obligations of the Company and the Guarantors are secured by first-priority liens on substantially all of the assets of the Company and the Guarantors, subject to certain exceptions.

Under the Amended Credit Agreement, the Company will pay to the administrative agent for the account of each revolving lender a commitment fee on a quarterly basis based on amounts committed but unused under the revolving facility from 0.20% to 0.40% per annum depending on the Company’s Total Net Leverage Ratio (as defined in the Amended Credit Agreement). The Company is also obligated to pay the administrative agent customary fees for credit facilities of this size and type.

Revolving borrowings under the Amended Credit Agreement bear interest at a rate per annum equal to (i) the Term SOFR Rate for the interest period plus the Applicable Rate (as defined in the Amended Credit Agreement) based on the Company’s Total Net Leverage Ratio or (ii) the Alternate Base Rate (as defined in the Amended Credit Agreement) as in effect from time to time plus the Applicable Rate based on the Company’s Total Net Leverage Ratio. As of September 30, 2023, the Applicable Rate for Term SOFR Loans is 1.25% per annum and the Applicable Rate for ABR Loans is 0.25% per annum. SOFR based loans also include a Credit Spread Adjustment based on the duration of the borrowing.

The Amended Credit Agreement contains affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants that, among other things, limit or restrict the ability of the Company and its subsidiaries, subject to negotiated exceptions, to incur additional indebtedness and additional liens on their assets, engage in mergers or acquisitions or dispose of assets, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions with affiliated persons, make investments and change the nature of their businesses. The Amended Credit Agreement also contains customary events of default, subject to thresholds and grace periods, including, among others, payment default, covenant default, cross default to other material indebtedness and judgment default. In addition, the Amended Credit Agreement requires the Company to maintain a Total Net Leverage Ratio of no more than 2.75 to 1.00 and an Interest Coverage Ratio of at least 3.50 to 1.00.

Table of Contents

As of September 30, 2023 and December 31, 2022, the Company had no borrowings outstanding under the Amended Credit Agreement and was in compliance with all covenants.

9. ACCELERATED SHARE REPURCHASE (“ASR”) PROGRAM

In the second quarter of fiscal 2022, the Company entered into an ASR agreement with JPMorgan Chase, National Association ("JPMorgan Chase") to purchase shares of its common stock from JPMorgan Chase for an aggregate purchase price of $100.0 million. Pursuant to the ASR program, the Company received an initial delivery of approximately 480 thousand shares of common stock based on the closing price of the common stock on May 31, 2022. Approximately 91 thousand additional shares of the Company's common stock were delivered upon termination of the agreement on August 8, 2022. The final number of shares delivered to the Company under the ASR agreement was based on the average of the daily volume-weighted average trading prices of the Company’s common stock during the term of the ASR program, less a discount.

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Note Regarding Forward-Looking Statements

Certain information in this report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Act”). These forward-looking statements generally can be identified by use of phrases or terminology such as “intend,” “anticipate,” “expect” or other similar words or the negative of such terminology. Similarly, descriptions of Medifast's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. These statements are based on the current expectations of our management and are subject to certain events, risks, uncertainties and other factors. These risks and uncertainties include, but are not limited to, those described in our 2022 Form 10-K and those described from time to time in our future reports filed with the SEC. Although Medifast believes that the expectations, statements and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this report. All of the forward-looking statements contained herein speak only as of the date of this report.

The following discussion should be read in conjunction with the unaudited condensed consolidated financial statements and related notes appearing elsewhere herein.

Overview

Medifast is the health and wellness company known for its habit-based and Coach-guided lifestyle solution OPTAVIA®, which provides people with a simple, yet comprehensive approach to help them achieve lasting optimal health and wellbeing. OPTAVIA offers clinically proven plans, scientifically developed products and a framework for habit creation reinforced by independent Coaches and Community support. As a physician-founded company with a 40+ year history, Medifast is a leader in the U.S. weight management industry, and has impacted more than 3 million lives to date. The company continues to innovate and build upon its scientific and clinical heritage to deliver on its mission of offering the world Lifelong Transformation, One Healthy Habit at a Time®.

Our OPTAVIA brand offers a highly competitive and effective lifestyle solution centered on developing new healthy habits through smaller, foundational changes called microHabits. OPTAVIA is built around four key components:

•Independent OPTAVIA Coaches: Coaches, about 90% of whom first started as Customers, provide individualized support and guidance to their Clients along their journeys to optimal health and wellbeing.

•OPTAVIA Community: A Community of like-hearted people provide each other with real-time connection and support.

•The Habits of Health® Transformational System: A proprietary evidence-based and holistic approach to lifestyle transformation which offers guidance on simple ways to create healthy habits in every area of life.

•Products & Plans: Lifestyle plans with clinically proven health benefits and scientifically developed products, backed by dietitians, scientists and physicians.

Table of Contents

We help customers achieve their health goals through a network of approximately 47,100 independent active earning OPTAVIA Coaches. OPTAVIA Coaches introduce customers to a set of healthy habits, in most cases starting with the habit of healthy eating, and offer exclusive OPTAVIA-branded “Fuelings.” Fuelings are nutrient-dense, portion-controlled, nutritionally interchangeable and simple to use. They are formulated with high-quality ingredients and are fortified with probiotic BC30™ cultures, vitamins and minerals, as well as other nutrients essential for good health. In the third quarter of 2023, the company announced OPTAVIA ACTIVE, a new line of premium exercise supplements and protein powders, OPTAVIA ACTIVE Essential Amino Acid (EAA) Blend and Whey Protein, designed to address age-related muscle mass decline and support muscle health. The new products work within existing OPTAVIA plans for those looking to achieve or maintain their optimal weight but also are a great solution for people wanting to enhance their health and wellbeing through movement. Our products support the process of integrating healthy habits into our customers’ day-to-day lives.

The OPTAVIA coaching model is customer-centric and boasts an energized health and wellness community. It promotes holistic health and wellness and positions healthy weight as a catalyst to greater lifestyle changes. OPTAVIA Coaches provide personalized support to customers and motivate them by sharing their passion for healthy living and lifestyle transformation.

OPTAVIA Coaches are another key to our success, as they share their own health and wellness experience and attract new customers, a portion of whom go on to become OPTAVIA Coaches. We offer economic incentives designed to support each OPTAVIA Coach’s long-term success, providing the opportunity to improve their finances while supporting the healthy lifestyles in their families and communities they interact with.1

OPTAVIA Coaches are independent contractors, not employees, who support customers and market our products and services to friends, family and other acquaintances, primarily through word of mouth, email and social media channels such as Facebook, Instagram, X (formerly known as Twitter) and video conferencing platforms. Products are shipped directly to OPTAVIA customers. OPTAVIA Coaches do not handle inventory or deliver merchandise to customers. This arrangement frees our OPTAVIA Coaches from having to manage inventory and allows them to maintain an arms-length transactional relationship while focusing their attention on support and encouragement.

We measure our success by the results our customers are able to achieve. The more OPTAVIA Coaches we have, the more customers we can serve. We believe our Coach-based model is scalable and drives both customer success and growth. We expect our continued investment in fostering a robust community around our OPTAVIA brand and Coaching model will continue to drive a sustainable, repeatable business rhythm focused on our mission of offering the world Lifelong Transformation, One Healthy Habit at a Time.

Our operations are conducted through our wholly owned subsidiaries, Jason Pharmaceuticals, Inc., OPTAVIA, LLC, Jason Enterprises, Inc., Jason Properties, LLC, Seven Crondall Associates, LLC, Corporate Events, Inc., OPTAVIA (Hong Kong) Limited, OPTAVIA (Singapore) PTE. LTD and OPTAVIA Health Consultation (Shanghai) Co., Ltd.

Recent Initiatives

The Company’s Fuel for the Future program is intended to optimize spending through value engineering, operational efficiency and improved procurement, and is expected to free up capital to invest in growth initiatives and raise margins. As a part of these efforts and due to economic changes in the Asia-Pacific region following the COVID-19 pandemic, Medifast exited its operations in Hong Kong and Singapore as of July 1, 2023. This departure was executed with the intention to help better prioritize resources that were previously dedicated to these markets in order to support initiatives that the Company anticipates will have a greater impact on revenues and profitability. This includes investing in technology and digital capabilities as well as rolling out product offerings that are complementary to its existing program, bringing OPTAVIA to new demographics and expanding the Company's total addressable market.

Additionally, on July 27, 2023, the Company announced a new product line, which was launched to customers in September 2023, OPTAVIA ACTIVE, which includes premium amino acid supplements and protein powders, OPTAVIA ACTIVE Essential Amino Acid (EAAs) Blend and OPTAVIA ACTIVE Whey Protein, with other products expected to be rolled out in 2024. Both the EAA Blend and the Whey Protein are designed to help new and existing customers of all fitness levels. With the announcement of the new product line, the Company targets new customer demographic segments and triples its total addressable market by entering the sports nutrition category, a $30 billion market. Further, the new product line is expected to extend the lifetime value of customers by extending their time with their OPTAVIA Coach as customers learn to live the habit of healthy motion. Finally, the new products also extend our offerings by adding exercise, making OPTAVIA a strong choice for those interested in using lifestyle modification along with the support of medically supported weight loss. Formulated to

1 OPTAVIA makes no guarantee of financial success. Success with OPTAVIA results from successful sales efforts, which require hard work, diligence, skill, persistence, competence, and leadership. Please see the OPTAVIA Income Disclosure Statement (http://bit.ly/idsOPTAVIA) for statistics on actual earnings of Coaches.

Table of Contents

work with or without OPTAVIA nutrition plans and guided by Coach support, OPTAVIA ACTIVE, similar to the Company’s other lines of products, is backed by science, made with no colors, flavors or sweeteners from artificial sources and is Informed Sport certified, which is a global standard in sports nutrition quality control that ensures its certified products contain no banned substances.

Through a small pilot launched in June 2023, in partnership with a network of several telehealth providers, the Company began exploring a combination of its habit-based, Coach-guided solution, OPTAVIA, together with innovations in medically supported weight loss, including GLP-1 medications. These pilots have provided valuable insight around potential future positioning and approach. The compelling three-way partnership between customer, clinician and Coach appears to resonate with the customer base who is interested in medically supported weight loss.

Medifast plans to continue investing in its offer to support all areas of its proprietary Habits of Health Transformational System, which includes weight loss, motion, hydration, sleep, and other macro-habits. The Company is committed to innovating as the industry evolves to continue delivering evidence-based solutions that are effective in helping customers create healthy habits and reach their wellness goals.

The Company is also pursuing expanding the customer base with a focus on Hispanic demographic groups in the US, where Medifast is underrepresented. To better connect with this group, we have translated approximately 70% of our main materials and website into Spanish, and expect to translate the remaining 30% by the end of the year. In October, in conjunction with National Hispanic Heritage month, the Company executed its first ever Spanish-language social and digital pilot, intended to build brand awareness and to learn how to best market OPTAVIA’s clinically proven health benefits and scientifically developed products, plans, Coaches and community to this growing demographic. The goal is to leverage the learnings from the social and digital pilot, with an anticipated larger, more comprehensive media effort to the US Hispanic market in 2024. We believe that advancing our business in the US Hispanic demographic will help us set the stage for future expansion into Latin America.

Macroeconomic Conditions

An overall decline in the health of the economy and other factors impacting consumer spending, such as natural disasters, pandemics, geopolitical conflicts, inflation and potential worsening in economic conditions may affect consumer purchases and reduce demand for our products. These uncertainties make it challenging for our management to estimate our future business performance.

We are exposed to market risks from changes in commodity or other raw material prices. Rising inflation could impact our cost structure and put pressure on consumer spending. Increases in commodity prices or food costs, including as a result of inflation, could affect the global and U.S. economies and could also adversely impact our business, financial condition or results of operations. Our variable cost structure can be utilized to adapt to changing market conditions with potential actions including adjustments to our manufacturing, distribution and customer support infrastructure. In addition, adverse labor market conditions could constrain our ability to manufacture and deliver products or increase the associated costs. As a response, we may periodically take incremental pricing actions to offset supply chain costs, inflationary pressures, and adverse labor market conditions.

In addition, beginning in February 2022, the war in Ukraine and corresponding events have had, and could continue to have, adverse effects on regional and global markets. Further, as the Israeli/Palestinian conflict in Gaza develops, it could have a similarly adverse impact on consumer sentiment and regional and global markets. While our operations are not directly impacted by these events, the duration of hostilities and the vast array of sanctions and related events (including cyberattacks) cannot be predicted. As a result, those events present uncertainty and risk. To date, the war in Ukraine and conflict in Gaza has had no material impact on our business.

In response to changing macroeconomic conditions, the Company may take further actions that alter its business operations as may be required by governmental authorities, or that are determined to be in the best interests of employees, OPTAVIA Coaches and customers.

Critical Accounting Policies and Estimates

The preparation of our financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Management develops, and changes periodically, these estimates and assumptions based on historical experience and on various other factors that are believed to be reasonable under

Table of Contents

the circumstances. Actual results may differ from these estimates under different assumptions or conditions. There were no significant changes in our critical estimates during the first nine months of 2023.

Our unaudited condensed consolidated financial statements are prepared in accordance with GAAP. Our significant accounting policies are described in Note 2 to the audited consolidated financial statements included in the 2022 Form 10-K. We consider all of our significant accounting policies and estimates to be critical. During Q1 2023 we made a change to our customer terms and conditions (“Customer T&Cs”) that resulted in a change to our revenue recognition policy which is described below. There were no other significant changes in our critical accounting policies during the first nine months of 2023.

Revenue Recognition: Our revenue is derived primarily from point of sale transactions executed over an e-commerce platform for weight loss, weight management, and other healthy living products. Prior to a change in our Customer T&Cs in the first quarter of 2023, revenue was recognized upon receipt by the customer and net of discounts, rebates, promotional adjustments, price adjustments, allocated consideration to loyalty programs, and estimated returns. Upon the change of our Customer T&Cs, revenue is now recognized upon delivery to the shipping carrier and net of discounts, rebates, promotional adjustments, price adjustments, allocated consideration to loyalty programs, and estimated returns. The impact of this change to the quarter ended March 31, 2023 was an increase of approximately $9.1 million in revenue and $2.8 million of income from operations.

Revenue is recognized when control of the promised products is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for transferring those products. When determining whether the customer has obtained control of the products, we consider any future performance obligations.

A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in Accounting Standards Codification ("ASC") 606, Revenue from Contracts with Customers. A contract’s transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, each performance obligation is satisfied. Our contracts have performance obligations to fulfill and deliver products from the point of sale transaction along with the related customer reward programs.

Our performance obligations are satisfied at a point in time. Revenue from products transferred to customers at a point in time accounted for substantially all of our revenue for the nine months ended September 30, 2023 and 2022. Revenue on these contracts is recognized when the obligations under the terms of the contract with our customer are satisfied.

Our return policy allows for customer returns of consumable products within 30 days of purchase and upon our authorization. We adjust revenues for the products expected to be returned and a liability is recognized for expected refunds to customers. We estimate expected returns based on historical levels and project this experience into the future.

Our sales contracts may give customers the option to purchase additional products priced at a discount. Options to acquire additional products at a discount can come in many forms, such as customer reward programs and incentive offerings including pricing arrangements, and promotions.

We reduce the transaction price for customer reward programs and certain incentive offerings including pricing arrangements, promotions, and incentives that represent variable consideration and separate performance obligations. The Company accounts for sales rewards that provide the customer with a material right as a separate performance obligation of the transactions, and therefore allocates consideration between the initial sale of products and the customer reward program and incentive offering.

Amounts billed to customers for shipping and handling activities are treated as a promised service performance obligation and are recorded as revenue in our Consolidated Statements of Income upon fulfillment of the performance obligation. Shipping and handling costs incurred by the Company for the delivery of products to customers are considered a cost to fulfill the contract and are included in cost of sales in our Consolidated Statements of Income.

We expense OPTAVIA Coach compensation and credit card fees during the period in which the corresponding revenue is earned. These costs are recorded in selling, general and administrative expense in our Consolidated Statements of Income.

Overview of Results of Operations

Our product sales accounted for approximately 98% of our revenues for each of the three months ended September 30, 2023 and 2022.

Table of Contents

The following tables reflect our income statements (in thousands, except percentages):


	Three months ended September 30,
	2023			2022			$ Change		% Change

Revenue	$	235,869		$	390,398		$	(154,529)	(39.6)	%
Cost of sales	58,492			107,549			(49,057)		(45.6)	%
Gross profit	177,377			282,849			(105,472)		(37.3)	%

Selling, general, and administrative	151,868			234,693			(82,825)		(35.3)	%

Income from operations	25,509			48,156			(22,647)		(47.0)	%

Other income (expense)
Interest income (expense)	1,033			(261)			1,294		495.8	%
Other income (expense)	7			(17)			24		141.2	%
	1,040			(278)			1,318		474.1	%

Income from operations before income taxes	26,549			47,878			(21,329)		(44.5)	%

Provision for income taxes	3,418			11,723			(8,305)		(70.8)	%

Net income	$	23,131		$	36,155		$	(13,024)	(36.0)	%

% of revenue
Gross profit	75.2		%	72.5		%
Selling, general, and administrative costs	64.4		%	60.1		%
Income from operations	10.8		%	12.3		%

Table of Contents


	Nine months ended September 30,
	2023			2022			$ Change		% Change

Revenue	$	881,039		$	1,261,332		(380,293)		(30.2)	%
Cost of sales	246,558			354,515			(107,957)		(30.5)	%
Gross profit	634,481			906,817			(272,336)		(30.0)	%

Selling, general, and administrative	516,755			754,610			(237,855)		(31.5)	%

Income from operations	117,726			152,207			(34,481)		(22.7)	%

Other income (expense)
Interest income (expense)	1,314			(519)			1,833		353.2	%
Other expense	(45)			(37)			(8)		(21.6)	%
	1,269			(556)			1,825		328.2	%

Income from operations before income taxes	118,995			151,651			(32,656)		(21.5)	%

Provision for income taxes	25,615			34,601			(8,986)		(26.0)	%

Net income	$	93,380		$	117,050		$	(23,670)	(20.2)	%

% of revenue
Gross profit	72.0		%	71.9		%
Selling, general, and administrative costs	58.7		%	59.8		%
Income from operations	13.4		%	12.1		%

Revenue: Revenue decreased $154.5 million, or 39.6%, to $235.9 million for the three months ended September 30, 2023 from $390.4 million for the three months ended September 30, 2022. The decline in revenue for the three months ended September 30, 2023 was primarily driven by a decrease in the number of active earning OPTAVIA Coaches to 47,100 as of September 30, 2023 from 66,200 as of September 30, 2022 and the decline in the productivity per active earning OPTAVIA Coach. The average revenue per active earning OPTAVIA Coach was $5,008 for the three months ended September 30, 2023 compared to $5,897 for the three months ended September 30, 2022. Revenue decreased $380.3 million, or 30.2%, to $881.0 million for the nine months ended September 30, 2023 from $1,261.3 million for the nine months ended September 30, 2023. The decline in revenue for the nine months ended September 30, 2023 was driven by a decrease in the number of active earning OPTAVIA Coaches and the decline in productivity per active earnings OPTAVIA Coach, partially offset by a $9.1 million impact from a timing difference related to changes in the Company’s sales order terms and conditions with its customers in the first quarter. The average revenue per active earning OPTAVIA Coach was $5,545 for the nine months ended September 30, 2023 compared to $6,367 for the nine months ended September 30, 2022. The decrease in productivity per active earning OPTAVIA Coach for the three months ended September 30, 2023 and nine months ended September 30, 2023 was driven by continued pressure on customer acquisition, partially offset by a price increase implemented in November 2022.

Cost of sales: Cost of sales decreased $49.1 million, or 45.6%, to $58.5 million from $107.5 million for the three months ended September 30, 2023 from the corresponding period in 2022. The decrease in cost of sales for the three months ended September 30, 2023 was primarily driven by decreased volumes, efficiencies in inventory management and lower supply chain costs including benefits from the optimization of our distribution center footprint. These decreases are partially offset by higher product costs resulting from inflationary pressures on raw ingredient costs, shipping costs, and labor costs. Cost of sales decreased $108.0 million, or 30.5%, to $246.6 million from $354.5 million for the nine months ended September 30, 2023. The decrease in cost of sales for the nine months ended September 30, 2023 was primarily driven by decreased volumes, partially offset by higher product costs resulting from inflationary pressures on raw ingredient costs, shipping costs, and labor costs.

Gross profit: Gross profit decreased $105.5 million, or 37.3%, to $177.4 million from $282.8 million for the three months ended September 30, 2023 from the corresponding period in 2022. The decrease in gross profit for the three months ended

Table of Contents

September 30, 2023 was due to lower revenue. As a percentage of revenue, gross profit increased 270 basis points to 75.2% for the three months ended September 30, 2023 from 72.5% for the corresponding period in 2022. Gross profit as a percentage of revenue was positively impacted by efficiencies in inventory management and lower supply chain costs including benefits from the optimization of our distribution center footprint. For the nine months ended September 30, 2023, gross profit decreased $272.3 million, or 30.0%, to $634.5 million from $906.8 million for the nine months ended September 30, 2023. The decrease in gross profit for the nine months ended September 30, 2023 was due to lower revenue as well as cost inflation from raw ingredient costs, shipping costs, and labor costs. As a percentage of revenue, gross profit increased 10 basis points to 72.0% for the nine months ended September 30, 2023 from 71.9% for the corresponding period in 2022.

Selling, general, and administrative: SG&A expenses were $151.9 million for the three months ended September 30, 2023, a decrease of $82.8 million, or 35.3%, as compared to $234.7 million from the corresponding period in 2022. SG&A expenses decreased for the three months ended September 30, 2023 primarily due to decreased Coach compensation on lower volumes and fewer active earning Coaches, as well as progress on several cost reduction and optimization initiatives, and charitable donations in 2022. As a percentage of revenue, SG&A expenses were 64.4% for the three months ended September 30, 2023 as compared to 60.1% for the corresponding period in 2022. SG&A expenses as a percentage of revenue increased for the three months ended September 30, 2023 primarily reflecting the loss of leverage on fixed costs due to lower sales volumes compared to 2022 as well as market research and investment costs related to medically supported weight loss activities. SG&A expenses included research and development costs of $1.3 million and $1.1 million for the three months ended September 30, 2023 and 2022, respectively, in connection with the development of new products, programs and clinical research activities. SG&A expenses were $516.8 million for the nine months ended September 30, 2023, a decrease of $237.9 million, or 31.5%, as compared to $754.6 million from the corresponding period in 2022. As a percentage of revenue, SG&A expenses were 58.7% for the nine months ended September 30, 2023 as compared to 59.8% for the corresponding period in 2022 primarily reflecting progress on several cost reduction and optimization initiatives and charitable donations in 2022, partially offset by the loss of leverage on fixed costs due to lower sales volumes compared to 2022. SG&A expenses included research and development costs of $3.4 million and $3.3 million for the nine months ended September 30, 2023 and 2022, respectively, in connection with the development of new products and programs and clinical research activities. SG&A expenses decreased for the nine months ended September 30, 2023 primarily due to decreased Coach compensation on lower volumes and fewer active earning Coaches, as well as progress on several cost reduction and optimization initiatives, and charitable donations in 2022.

Income from operations: For the three months ended September 30, 2023, income from operations decreased $22.6 million to $25.5 million from $48.2 million for the corresponding period in 2022 primarily as a result of decreased gross profit partially offset by decreased SG&A expenses. Income from operations as a percentage of revenue decreased to 10.8% for the three months ended September 30, 2023 from 12.3% for the corresponding period in 2022 due to the factors described above impacting SG&A expenses, partially offset by the factors impacting gross profit. For the nine months ended September 30, 2023, income from operations decreased $34.5 million to $117.7 million from $152.2 million for the corresponding period in 2022 primarily as a result of decreased gross profit partially offset by decreased SG&A expenses. Income from operations as a percentage of revenue increased to 13.4% for the nine months ended September 30, 2023 from 12.1% for the corresponding period in 2022 due to the factors above impacting gross profit and SG&A expenses.

Provision for income taxes: For the three months ended September 30, 2023, the Company recorded $3.4 million in income tax expense, an effective tax rate of 12.9%, as compared to $11.7 million in income tax expense, an effective tax rate of 24.5%, for the three months ended September 30, 2022. The decrease in the effective tax rate for the three months ended September 30, 2023 was primarily driven by the increase in the tax benefit for charitable donations of inventory, an increase in research and development tax credits, and a decrease in state income taxes. During the quarter ended September 30, 2023, the Company completed its 2022 Federal income tax return, which included an update to the estimated tax-basis cost of charitable donations of inventory and the estimated research and development tax credits. For the nine months ended September 30, 2023, the Company recorded $25.6 million in income tax expense, an effective tax rate of 21.5%, as compared to $34.6 million in income tax expense, an effective tax rate of 22.8%, for the nine months ended September 30, 2022. The decrease in the effective tax rate for the nine months ended September 30, 2022 was primarily driven by the increase in the tax benefit for charitable donations of inventory.

Net income: Net income was $23.1 million and $93.4 million, or $2.12 and $8.55 per diluted share for the three and nine months ended September 30, 2023 as compared to $36.2 million and $117.1 million, or $3.27 and $10.30 per diluted share, for the three and nine months ended September 30, 2022. The period-over-period changes were driven by the factors described above.

Liquidity and Capital Resources

The Company had stockholders’ equity of $193.0 million and working capital of $114.2 million at September 30, 2023 as compared with $155.0 million and $81.9 million at December 31, 2022, respectively. The $38.0 million net increase in

Table of Contents

stockholders’ equity reflects $93.4 million in net income for the nine months ended September 30, 2023 offset by $3.6 million used for repurchases of the Company’s common stock and $54.5 million for dividends paid to holders of the Company’s common stock as well as the other equity transactions described in the “Condensed Consolidated Statements of Changes in Stockholders’ Equity” included in this report. On September 7, 2023, the Company declared a quarterly dividend of $1.65 per share payable on November 7, 2023, to stockholders of record as of September 19, 2023. Future share repurchases and the payment of any future dividends are subject to the business judgment of our Board of Directors, taking into consideration our historical and projected results of operations, financial condition, cash flows, capital requirements, industry conditions, covenant compliance, changes in laws and regulations, current economic environment and other factors considered relevant. The Company’s cash, cash equivalents and investment securities increased from $87.7 million at December 31, 2022 to $157.8 million at September 30, 2023.

Net cash provided by operating activities decreased by $5.7 million to $137.1 million for the nine months ended September 30, 2023 from $142.8 million for the nine months ended September 30, 2022 primarily driven by a $25.9 million increase related to changes in inventory balances, a $6.1 million increase in prepaid expenses and other current assets, a $3.9 million increase in other assets, an increase of $1.7 million in depreciation and amortization expenses, offset by a $23.7 million decrease in net income, a $2.3 million reduction in share-based compensation, a $3.8 million reduction in deferred income taxes, a $1.2 million reduction in non-cash lease expense, and a $13.1 million reduction in accounts payable and accrued expenses. We decreased our inventory purchases during the period ended September 30, 2023 to align with sales demand. Accounts payable and accrued expenses decreased due to the timing of payments.

Net cash used in investing activities was $50.3 million for the nine months ended September 30, 2023 as compared to $2.4 million for the nine months ended September 30, 2022. The increase was primarily due to the purchase of investment securities during the nine months ended September 30, 2023. Net cash used in financing activities decreased by $113.4 million to $61.9 million for the nine months ended September 30, 2023 from $175.3 million for the nine months ended September 30, 2022. This decrease was primarily due to the $100.0 million accelerated share repurchase (“ASR”) program as of June 30, 2022 that did not recur in 2023, a $16.4 million decrease in other repurchases of the Company’s common stock, partially offset by a $1.8 million increase in net shares repurchased for taxes and an increase of $1.3 million of cash dividends paid to stockholders.

In pursuing its business strategy, the Company may require additional cash for operating and investing activities. The Company expects future cash requirements in both the short term and the long term, if any, to be funded from operating cash flow and financing activities.

From time to time, the Company evaluates potential acquisitions that complement our business. If consummated, any such transactions may use a portion of our working capital or require the issuance of equity or debt. We have no present understandings, commitments or agreements with respect to any material acquisitions.

On April 13, 2021, the Company and certain of its subsidiaries (collectively, the “Guarantors”) entered into a credit agreement among the Company, the Guarantors, the lenders party thereto and Citibank, N.A., in its capacity as administrative agent. On May 31, 2022, the Credit Agreement was amended to increase the borrowing capacity and convert the interest rate to be based on SOFR, from LIBOR (the “Amended Credit Agreement”). The Amended Credit Agreement provides for a $225.0 million senior secured revolving credit facility with a $20.0 million letter of credit sublimit. The Amended Credit Agreement also provides for an uncommitted incremental facility that permits the Company, subject to certain conditions, to increase the senior secured revolving credit facility by up to $100.0 million. The Amended Credit Agreement contains affirmative and negative covenants customarily applicable to credit facilities. As of September 30, 2023, the Company had no borrowings under the credit facility and was in compliance with all of its debt covenants.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Market risk is the potential loss arising from adverse changes in market rates and prices, such as interest rates and a decline in the stock market. The Company does not enter into derivatives, foreign exchange transactions or other financial instruments for trading or speculative purposes.

The Company is exposed to market risk related to changes in interest rates and market pricing impacting our credit facility and investment portfolio. Its current investment policy is to maintain an investment portfolio consisting of corporate bonds and U.S. money market securities directly or through managed funds. Its cash is deposited in and invested through highly rated financial institutions in North America. Its marketable securities are subject to interest rate risk and market pricing risk and will fall in value if market interest rates increase or if market pricing decreases. If market interest rates were to increase and market pricing were to decrease immediately and uniformly by 10% from levels at September 30, 2023, the Company estimates that the fair value of its investment portfolio would decline by an immaterial amount and therefore it would not expect its operating results or cash flows to be affected to any significant degree by the effect of a change in market conditions on our investments. As of September 30, 2023 the Company also did not have any outstanding borrowings.

Table of Contents

There have been no material changes to our market risk exposure since December 31, 2022.

Item 4. Controls and Procedures

Management, including our Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Act, as amended, as of September 30, 2023. Our disclosure controls and procedures are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Act is recorded, processed, summarized and reported accurately and on a timely basis. Based on this evaluation performed in accordance with the criteria established in the 2013 Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission, our management concluded that the Company’s disclosure controls and procedures are effective at the reasonable assurance level as of the end of the period covered by this report.

Changes in Internal Control over Financial Reporting

There have been no material changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Act) during the fiscal quarter ended September 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

Part II Other Information

Item 1. Legal Proceedings

The Company is, from time to time, subject to a variety of litigation and similar proceedings that arise out of the ordinary course of its business. Based upon the Company’s experience, current information and applicable law, it does not believe that these proceedings and claims will have a material adverse effect on its results of operations, financial position or liquidity. However, the results of legal actions cannot be predicted with certainty. Therefore, it is possible that the Company’s results of operations, financial condition or cash flows could be materially adversely affected in any particular period by the unfavorable resolution of one or more legal actions.

Item 1A. Risk Factors

There have been no material changes to the risk factors set forth in Part I, Item 1A of the 2022 Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities


2023	Total Number of Shares Purchased (1)	Average Price Paid per Share	Total Number of Shares Purchased as Part of a Publicly Announced Plan or Program	Maximum Number of Shares that May Yet Be Purchased Under the Plans or Programs (2)
July 1 - July 31	1,146	94.54	—	1,323,568
August 1 - August 31	17	84.40	—	1,323,568
September 1 - September 30	23	77.56	—	1,323,568

(1)All of the shares of the Company’s common stock reflected in this column were surrendered by employees and directors to the Company to cover minimum tax liability withholding obligations upon the exercise of stock options or the vesting of shares of restricted stock and performance-based share awards previously granted to such employees and directors.

(2)At the outset of the quarter ended September 30, 2023, there were 1,323,568 shares of the Company’s common stock eligible for repurchase under the stock repurchase authorization dated September 16, 2014 (the "Stock Repurchase Plan").

As of September 30, 2023, there were 1,323,568 shares of the Company’s common stock eligible for repurchase under the Stock Repurchase Plan. There can be no assurances as to the amount, timing or prices of repurchases, which may vary based on market conditions and other factors. The Stock Repurchase Plan does not have an expiration date and can be modified or terminated by the Board of Directors at any time.

Table of Contents

Item 6. Exhibits


Exhibit Number						Description of Exhibit

3.1						Restated and Amended Certificate of Incorporation of Medifast, Inc. (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K (File No. 001-31573) filed February 27, 2015).

3.2						Amended and Restated Bylaws of Medifast, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Amendment No. 1 Current Report on Form 8-K (File No. 001-31573) filed on December 4, 2019).

31.1						Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

31.2						Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

32.1						Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).



101						The following financial statements from Medifast, Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 filed November 6, 2023, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Statements of Income, (ii) Condensed Consolidated Statements of Comprehensive Income, (iii) Condensed Consolidated Balance Sheets, (iv) Condensed Consolidated Statements of Cash Flows, (v) Condensed Consolidated Statements of Changes in Stockholders’ Equity, and (vi) Notes to the Condensed Consolidated Financial Statements (filed herewith).

104						Cover Page Interactive Data File - The cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

In accordance with SEC Release No. 33-8238, Exhibit 32.1 is being furnished and not filed.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Medifast, Inc.


By:			/s/ DANIEL R. CHARD
			Daniel R. Chard
			Chief Executive Officer
			(Principal Executive Officer)

Dated:			November 6, 2023


			/s/ JAMES P. MALONEY
			James P. Maloney
			Chief Financial Officer
			(Principal Financial Officer)

Dated:			November 6, 2023

Exhibit 31.1

RULE 13a-14(a) CERTIFICATION

I, Daniel R. Chard, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Medifast, Inc. (the “Registrant”);

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4.The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

5.The Registrant’s other certifying officer and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information; and

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.


Date:	November 6, 2023	/s/ Daniel R. Chard
		Daniel R. Chard
		Chief Executive Officer

Exhibit 31.2

RULE 13a-14(a) CERTIFICATION

I, James P. Maloney, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Medifast, Inc. (the “Registrant”);

4.I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

5.I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s internal control over financial reporting.


Date:	November 6, 2023	/s/ James P. Maloney
		James P. Maloney
		Chief Financial Officer

Exhibit 32.1

MEDIFAST, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q (the “Report”) for the quarter ended September 30, 2023 of Medifast, Inc. (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Daniel R. Chard, Chief Executive Officer and I, James P. Maloney, Chief Financial Officer, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of the operations of the Company.


By:			/s/ DANIEL R. CHARD
			Daniel R. Chard
			Chief Executive Officer
			November 6, 2023


			/s/ JAMES P. MALONEY
			James P. Maloney
			Chief Financial Officer
			November 6, 2023

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2023	Oct. 23, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-31573
Entity Registrant Name	Medifast, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	13-3714405
Entity Address, Address Line One	100 International Drive
Entity Address, City or Town	Baltimore
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	21202
City Area Code	410
Local Phone Number	581-8042
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	MED
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		10,892,602
Entity Central Index Key	0000910329
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Amendment Flag	false

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Revenue	$ 235,869	$ 390,398	$ 881,039	$ 1,261,332
Cost of sales	58,492	107,549	246,558	354,515
Gross profit	177,377	282,849	634,481	906,817
Selling, general, and administrative	151,868	234,693	516,755	754,610
Income from operations	25,509	48,156	117,726	152,207
Other income (expense)
Interest income (expense)	1,033	(261)	1,314	(519)
Other income (expense)	7	(17)	(45)	(37)
Total other income (expense)	1,040	(278)	1,269	(556)
Income from operations before income taxes	26,549	47,878	118,995	151,651
Provision for income taxes	3,418	11,723	25,615	34,601
Net income	$ 23,131	$ 36,155	$ 93,380	$ 117,050
Earnings per share
Basic (in usd per share)	$ 2.12	$ 3.30	$ 8.58	$ 10.37
Diluted (in usd per share)	$ 2.12	$ 3.27	$ 8.55	$ 10.30
Weighted average shares outstanding
Basic (in shares)	10,892	10,964	10,881	11,290
Diluted (in shares)	10,933	11,042	10,925	11,369
Cash dividends declared per share (in usd per share)	$ 1.65	$ 1.64	$ 4.95	$ 4.92

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Net income	$ 23,131	$ 36,155	$ 93,380	$ 117,050
Other comprehensive income, net of tax:
Foreign currency translation	27	123	125	300
Unrealized losses on investment securities	(9)	0	(9)	(21)
Other comprehensive income, net of tax	18	123	116	279
Comprehensive income	$ 23,149	$ 36,278	$ 93,496	$ 117,329

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current Assets
Cash and cash equivalents	$ 112,751	$ 87,691
Investment securities	45,009	0
Inventories	58,227	118,856
Prepaid expenses and other current assets	8,289	16,237
Total current assets	224,276	222,784
Property, plant and equipment - net of accumulated depreciation	53,484	57,185
Right-of-use assets	15,681	18,460
Other assets	15,753	12,456
Deferred tax assets	10,825	5,328
TOTAL ASSETS	320,019	316,213
Current Liabilities
Accounts payable and accrued expenses	103,223	134,690
Income taxes payable	1,417	428
Current lease obligations	5,472	5,776
Total current liabilities	110,112	140,894
Lease obligations, net of current lease obligations	16,872	20,275
Total liabilities	126,984	161,169
Stockholders' Equity
Common stock, par value $0.001 per share: 20,000 shares authorized; 10,892 and 10,928 issued and 10,892 and 10,873 outstanding at September 30, 2023 and December 31, 2022, respectively	11	11
Additional paid-in capital	24,107	21,555
Accumulated other comprehensive income	141	24
Retained earnings	168,776	139,852
Less: treasury stock at cost, 0 and 54 shares at September 30, 2023 and December 31, 2022, respectively	0	(6,398)
Total stockholders' equity	193,035	155,044
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 320,019	$ 316,213

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value (in usd per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	20,000,000	20,000,000
Common stock, issued (in shares)	10,892,000	10,928,000
Common stock, outstanding (in shares)	10,892,000	10,873,000
Treasury stock at cost (in shares)	0	54,000

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Operating Activities
Net income	$ 93,380	$ 117,050
Adjustments to reconcile net income to cash provided by operating activities
Depreciation and amortization	9,754	8,026
Non-cash lease expense	3,532	4,740
Share-based compensation	5,795	8,103
Loss on sale or disposal of property, plant and equipment	622	0
Amortization of premium on investment securities	0	14
Deferred income taxes	(5,497)	(1,746)
Change in operating assets and liabilities:
Inventories	60,629	34,764
Prepaid expenses and other current assets	7,948	1,889
Other assets	(4,674)	(8,545)
Accounts payable and accrued expenses	(35,343)	(22,259)
Income taxes payable	989	795
Net cash flow provided by operating activities	137,135	142,831
Investing Activities
Sale and maturities of investment securities	0	5,267
Purchase of investment securities	(44,779)	0
Purchase of property and equipment	(5,537)	(7,617)
Net cash flow used in investing activities	(50,316)	(2,350)
Financing Activities
Options exercised by directors	105	0
Net shares repurchased for employee taxes	(3,348)	(1,504)
Cash dividends paid to stockholders	(55,039)	(53,698)
Stock repurchases	(3,602)	(120,048)
Net cash flow used in financing activities	(61,884)	(175,250)
Foreign currency impact	125	296
Increase (Decrease) in cash and cash equivalents	25,060	(34,473)
Cash and cash equivalents - beginning of the period	87,691	104,183
Cash and cash equivalents - end of period	112,751	69,710
Supplemental disclosure of cash flow information:
Income taxes paid	30,169	33,906
Dividends declared included in accounts payable	$ 19,184	$ 19,395

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income	Retained Earnings	Treasury Stock
Balance (in shares) at Dec. 31, 2021		11,594
Balance at Dec. 31, 2021	$ 202,474	$ 12	$ 12,018	$ 111	$ 190,333	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	41,781				41,781
Share-based compensation (in shares)		18
Share-based compensation	2,275		2,275
Net shares repurchased for employee taxes (in shares)		(8)
Net shares repurchased for employee taxes	(1,459)		(1,459)
Treasury stock from stock repurchases	(10,000)					(10,000)
Treasury stock retired from stock repurchases (in shares)		(51)
Treasury stock retired from stock repurchases	0				(10,000)	10,000
Other comprehensive income	16			16
Cash dividends declared to stockholders	(19,063)				(19,063)
Balance (in shares) at Mar. 31, 2022		11,553
Balance at Mar. 31, 2022	216,024	$ 12	12,834	127	203,051	0
Balance (in shares) at Dec. 31, 2021		11,594
Balance at Dec. 31, 2021	202,474	$ 12	12,018	111	190,333	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	$ 117,050
Options exercised by directors (in shares)	0
Other comprehensive income	$ 279
Balance (in shares) at Sep. 30, 2022		10,929
Balance at Sep. 30, 2022	150,522	$ 11	18,617	391	131,503	0
Balance (in shares) at Mar. 31, 2022		11,553
Balance at Mar. 31, 2022	216,024	$ 12	12,834	127	203,051	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	39,113				39,113
Share-based compensation (in shares)		1
Share-based compensation	2,865		2,865
Net shares repurchased for employee taxes	(20)		(20)
Treasury stock from stock repurchases	(90,038)					(90,038)
Treasury stock retired from stock repurchases (in shares)		(535)
Treasury stock retired from stock repurchases	(1)	$ (1)			(90,038)	90,038
Stock Repurchases, not yet settled	(20,010)		(15,679)		(4,331)
Other comprehensive income	141			141
Cash dividends declared to stockholders	(18,598)				(18,598)
Balance (in shares) at Jun. 30, 2022		11,019
Balance at Jun. 30, 2022	129,476	$ 11	0	268	129,197	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	36,155				36,155
Share-based compensation (in shares)		1
Share-based compensation	2,963		2,963
Net shares repurchased for employee taxes	(25)		(25)
Treasury stock from stock repurchases	(20,010)					(20,010)
Treasury stock retired from stock repurchases (in shares)		(91)
Treasury stock retired from stock repurchases	0				(20,010)	20,010
Settlement of accelerated share repurchase agreement	20,010		15,679		4,331
Other comprehensive income	123			123
Cash dividends declared to stockholders	(18,170)				(18,170)
Balance (in shares) at Sep. 30, 2022		10,929
Balance at Sep. 30, 2022	$ 150,522	$ 11	18,617	391	131,503	0
Balance (in shares) at Dec. 31, 2022	10,928	10,928
Balance at Dec. 31, 2022	$ 155,044	$ 11	21,555	24	139,852	(6,398)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	39,968				39,968
Share-based compensation (in shares)		69
Share-based compensation	606		606
Options exercised by directors (in shares)		4
Options exercised by directors	105		105
Net shares repurchased for employee taxes (in shares)		(30)
Net shares repurchased for employee taxes	(3,236)		(3,236)
Treasury stock from stock repurchases	(3,602)					(3,602)
Treasury stock retired from stock repurchases (in shares)		(84)
Treasury stock retired from stock repurchases	0				(10,000)	10,000
Other comprehensive income	9			9
Cash dividends declared to stockholders	(17,994)				(17,994)
Balance (in shares) at Mar. 31, 2023		10,887
Balance at Mar. 31, 2023	$ 170,900	$ 11	19,030	33	151,826	0
Balance (in shares) at Dec. 31, 2022	10,928	10,928
Balance at Dec. 31, 2022	$ 155,044	$ 11	21,555	24	139,852	(6,398)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	$ 93,380
Options exercised by directors (in shares)	4
Other comprehensive income	$ 116
Balance (in shares) at Sep. 30, 2023	10,892	10,892
Balance at Sep. 30, 2023	$ 193,035	$ 11	24,107	141	168,776	0
Balance (in shares) at Mar. 31, 2023		10,887
Balance at Mar. 31, 2023	170,900	$ 11	19,030	33	151,826	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	30,280				30,280
Share-based compensation (in shares)		2
Share-based compensation	2,514		2,514
Net shares repurchased for employee taxes	(2)		(2)
Other comprehensive income	90			90
Cash dividends declared to stockholders	(18,221)				(18,221)
Balance (in shares) at Jun. 30, 2023		10,889
Balance at Jun. 30, 2023	185,561	$ 11	21,542	123	163,885	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	23,131				23,131
Share-based compensation (in shares)		4
Share-based compensation	2,675		2,675
Net shares repurchased for employee taxes (in shares)		(1)
Net shares repurchased for employee taxes	(110)		(110)
Other comprehensive income	18			18
Cash dividends declared to stockholders	$ (18,240)				(18,240)
Balance (in shares) at Sep. 30, 2023	10,892	10,892
Balance at Sep. 30, 2023	$ 193,035	$ 11	$ 24,107	$ 141	$ 168,776	$ 0

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Sep. 30, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation - The accompanying unaudited condensed consolidated financial statements of Medifast, Inc. and its wholly-owned subsidiaries (“Medifast,” the “Company,” “we,” “us,” or “our”) included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim reporting and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and notes that are normally required by GAAP have been condensed or omitted. However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included and management believes the disclosures that are made are adequate to make the information presented not misleading. The condensed consolidated balance sheet at December 31, 2022 has been derived from the 2022 audited consolidated financial statements at that date included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (“2022 Form 10-K”). The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of results that may be expected for the fiscal year ending December 31, 2023. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in the 2022 Form 10-K. Presentation of Financial Statements - The unaudited condensed consolidated financial statements included herein include the accounts of the Company. All significant intercompany accounts and transactions have been eliminated. Use of Estimates - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates. Recently Issued Accounting Pronouncements - The Company has not adopted any new accounting standards during the nine months ended September 30, 2023. There are no recently issued accounting pronouncements that are expected to have a material effect on the Company’s financial position, results of operations, cash flows, or disclosures.

INVENTORIES

9 Months Ended

Sep. 30, 2023

Inventory Disclosure [Abstract]

INVENTORIES

Inventories consisted of the following (in thousands):


	September 30, 2023		December 31, 2022

Raw materials	$	8,491	$	12,670
Packaging	2,269		3,611
Non-food finished goods	4,426		8,738
Finished goods	49,558		97,675
Reserve for obsolete inventory	(6,517)		(3,838)
Total	$	58,227	$	118,856

EARNINGS PER SHARE

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

EARNINGS PER SHARE

The following table sets forth the computation of basic and diluted EPS (in thousands, except per share data):


	Three months ended September 30,				Nine months ended September 30,
	2023		2022		2023		2022

Numerator:
Net income	$	23,131	$	36,155	$	93,380	$	117,050

Denominator:
Weighted average shares of common stock outstanding	10,892		10,964		10,881		11,290
Effect of dilutive common stock equivalents	41		78		44		79
Weighted average shares of common stock outstanding	10,933		11,042		10,925		11,369

Earnings per share - basic	$	2.12	$	3.30	$	8.58	$	10.37

Earnings per share - diluted	$	2.12	$	3.27	$	8.55	$	10.30

SHARE-BASED COMPENSATION

9 Months Ended

Sep. 30, 2023

Share-Based Payment Arrangement [Abstract]

SHARE-BASED COMPENSATION

Stock Options

The following table is a summary of our stock option activity (in thousands, except per share data):


	Nine months ended September 30,
	2023			2022
	Awards	Weighted-Average Exercise Price		Awards	Weighted-Average Exercise Price

Outstanding at beginning of period	33	$	54.98	33	$	54.98
Exercised	(4)	27.18		—	—
Outstanding at end of the period	29	$	58.65	33	$	54.98
Exercisable at end of the period	29	$	58.65	28	$	52.76

Restricted Stock

The following table summarizes our restricted stock activity (in thousands, except per share data):


	Nine months ended September 30,
	2023			2022
	Shares	Weighted-Average Grant Date Fair Value		Shares	Weighted-Average Grant Date Fair Value

Outstanding at beginning of period	60	$	188.11	44	$	183.51
Granted	86	97.96		38	176.60
Vested	(25)	169.46		(19)	156.16
Forfeited	(5)	142.11		(1)	186.53
Outstanding at end of the period	116	$	127.57	62	$	187.83

Market and Performance-based Share Awards


	Three months ended September 30,
	2023			2022
	Shares	Share-Based Compensation Expense		Shares	Share-Based Compensation Expense
Options and restricted stock	145	$	1,558	90	$	1,392
Market and performance-based share awards granted in 2023	47	487		—	—
Market and performance-based share awards granted in 2022	24	—		25	438
Performance-based share awards granted in 2021	14	620		15	654
Performance-based share awards granted in 2020	28	10		26	479
Total share-based compensation	258	$	2,675	156	$	2,963

The total expense during the nine months ended September 30, 2023 and 2022 as follows (in thousands):


	Nine months ended September 30,
	2023			2022
	Shares	Share-Based Compensation Expense		Shares	Share-Based Compensation Expense
Options and restricted stock	145	$	4,426	90	$	3,789
Market and performance-based share awards granted in 2023	47	1,048		—	—
Market and performance-based share awards granted in 2022	24	(1,388)		25	950
Performance-based share awards granted in 2021	14	1,600		15	1,941
Performance-based share awards granted in 2020	28	109		26	1,423
Total share-based compensation	258	$	5,795	156	$	8,103

LEASES

9 Months Ended

Sep. 30, 2023

Leases [Abstract]

LEASES

Operating Leases

Supplemental cash flow information related to the Company’s operating leases was as follows (in thousands):


	Nine months ended September 30,
	2023		2022

Cash paid for amounts included in the measurements of lease liabilities
Operating cash flow used in operating leases	$	4,838	$	5,413

Right-of-use assets obtained in exchange for lease obligations
Operating leases	$	753	$	103

As of September 30, 2023, the weighted average remaining lease term was 4 years, 2 months and the weighted average discount rate was 2.00%.

The following table presents the maturity of the Company’s operating lease liabilities as of September 30, 2023 (in thousands):


2023 (excluding the nine months ended September 30, 2023)	$	1,435
2024	5,955
2025	6,095
2026	4,438
2027	2,553
Thereafter	2,858
Total lease payments	$	23,334
Less: imputed interest	(990)
Total	$	22,344

ACCUMULATED OTHER COMPREHENSIVE INCOME

9 Months Ended

Sep. 30, 2023

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]

ACCUMULATED OTHER COMPREHENSIVE INCOME

The following table sets forth the components of accumulated other comprehensive income, net of tax where applicable (in thousands):


	September 30, 2023		December 31, 2022

Foreign currency translation	$	150	$	24
Unrealized net losses on investment securities	(9)		—
Accumulated other comprehensive (loss)/income	$	141	$	24

FINANCIAL INSTRUMENTS

9 Months Ended

Sep. 30, 2023

Investments, All Other Investments [Abstract]

FINANCIAL INSTRUMENTS

The following tables present the Company’s cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands):


	September 30, 2023
	Cost		Unrealized Gains (Losses)		Accrued Interest		Estimated Fair Value		Cash & Cash Equivalents		Investment Securities

Cash	$	107,656	$	—	$	—	$	107,656	$	107,656	$	—

Level 1:
Money market accounts	5,033		—		62		5,095		5,095		—
Government & agency securities	15,200		17		28		15,245		—		15,245

	20,233		17		90		20,340		5,095		15,245

Level 2:
Corporate bonds	29,579		(26)		211		29,764		—		29,764

Total	$	157,468	$	(9)	$	301	$	157,760	$	112,751	$	45,009


	December 31, 2022
	Cost		Unrealized Gains (Losses)		Accrued Interest		Estimated Fair Value		Cash & Cash Equivalents		Investment Securities

Cash	$	87,691	$	—	$	—	$	87,691	$	87,691	$	—

Level 1:
Money market accounts	—		—		—		—		—		—
Government & agency securities	—		—		—		—		—		—
	—		—		—		—		—		—




Total	$	87,691	$	—	$	—	$	87,691	$	87,691	$	—

The Company had no realized gain or loss for the three and nine months ended September 30, 2023 and 2022.

DEBT	9 Months Ended
DEBT	Sep. 30, 2023
Debt Disclosure [Abstract]
DEBT	DEBT Credit Agreement On April 13, 2021, the Company and certain of its subsidiaries (collectively, the “Guarantors”) entered into a credit agreement (the “Credit Agreement”) among the Company, the Guarantors, the lenders party thereto and Citibank, N.A., in its capacity as administrative agent. On May 31, 2022, the Credit Agreement was amended to increase the borrowing capacity and convert the interest rate to be based on Secured Overnight Financing Rate (“SOFR”), from London Inter-Bank Offered Rate (LIBOR) (the “Amended Credit Agreement”). The Amended Credit Agreement provides for a $225.0 million senior secured revolving credit facility with a $20.0 million letter of credit sublimit. The Amended Credit Agreement also provides for an uncommitted incremental facility that permits the Company, subject to certain conditions, to increase the senior secured revolving credit facility by up to $100.0 million. The Amended Credit Agreement matures on April 13, 2026. The Company’s obligations under the Amended Credit Agreement are guaranteed by the Guarantors. The obligations of the Company and the Guarantors are secured by first-priority liens on substantially all of the assets of the Company and the Guarantors, subject to certain exceptions. Under the Amended Credit Agreement, the Company will pay to the administrative agent for the account of each revolving lender a commitment fee on a quarterly basis based on amounts committed but unused under the revolving facility from 0.20% to 0.40% per annum depending on the Company’s Total Net Leverage Ratio (as defined in the Amended Credit Agreement). The Company is also obligated to pay the administrative agent customary fees for credit facilities of this size and type. Revolving borrowings under the Amended Credit Agreement bear interest at a rate per annum equal to (i) the Term SOFR Rate for the interest period plus the Applicable Rate (as defined in the Amended Credit Agreement) based on the Company’s Total Net Leverage Ratio or (ii) the Alternate Base Rate (as defined in the Amended Credit Agreement) as in effect from time to time plus the Applicable Rate based on the Company’s Total Net Leverage Ratio. As of September 30, 2023, the Applicable Rate for Term SOFR Loans is 1.25% per annum and the Applicable Rate for ABR Loans is 0.25% per annum. SOFR based loans also include a Credit Spread Adjustment based on the duration of the borrowing. The Amended Credit Agreement contains affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants that, among other things, limit or restrict the ability of the Company and its subsidiaries, subject to negotiated exceptions, to incur additional indebtedness and additional liens on their assets, engage in mergers or acquisitions or dispose of assets, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions with affiliated persons, make investments and change the nature of their businesses. The Amended Credit Agreement also contains customary events of default, subject to thresholds and grace periods, including, among others, payment default, covenant default, cross default to other material indebtedness and judgment default. In addition, the Amended Credit Agreement requires the Company to maintain a Total Net Leverage Ratio of no more than 2.75 to 1.00 and an Interest Coverage Ratio of at least 3.50 to 1.00. As of September 30, 2023 and December 31, 2022, the Company had no borrowings outstanding under the Amended Credit Agreement and was in compliance with all covenants.

ACCELERATED SHARE REPURCHASE ("ASR") PROGRAM	9 Months Ended
ACCELERATED SHARE REPURCHASE ("ASR") PROGRAM	Sep. 30, 2023
Equity [Abstract]
ACCELERATED SHARE REPURCHASE ("ASR") PROGRAM	ACCELERATED SHARE REPURCHASE (“ASR”) PROGRAMIn the second quarter of fiscal 2022, the Company entered into an ASR agreement with JPMorgan Chase, National Association ("JPMorgan Chase") to purchase shares of its common stock from JPMorgan Chase for an aggregate purchase price of $100.0 million. Pursuant to the ASR program, the Company received an initial delivery of approximately 480 thousand shares of common stock based on the closing price of the common stock on May 31, 2022. Approximately 91 thousand additional shares of the Company's common stock were delivered upon termination of the agreement on August 8, 2022. The final number of shares delivered to the Company under the ASR agreement was based on the average of the daily volume-weighted average trading prices of the Company’s common stock during the term of the ASR program, less a discount.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	Sep. 30, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation - The accompanying unaudited condensed consolidated financial statements of Medifast, Inc. and its wholly-owned subsidiaries (“Medifast,” the “Company,” “we,” “us,” or “our”) included herein have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim reporting and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and notes that are normally required by GAAP have been condensed or omitted. However, in the opinion of management, all adjustments consisting of normal, recurring adjustments considered necessary for a fair presentation of the financial position and results of operations have been included and management believes the disclosures that are made are adequate to make the information presented not misleading. The condensed consolidated balance sheet at December 31, 2022 has been derived from the 2022 audited consolidated financial statements at that date included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (“2022 Form 10-K”). The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of results that may be expected for the fiscal year ending December 31, 2023. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto, which are included in the 2022 Form 10-K.
Presentation of Financial Statements	Presentation of Financial Statements - The unaudited condensed consolidated financial statements included herein include the accounts of the Company. All significant intercompany accounts and transactions have been eliminated.
Use of Estimates	Use of Estimates - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements - The Company has not adopted any new accounting standards during the nine months ended September 30, 2023. There are no recently issued accounting pronouncements that are expected to have a material effect on the Company’s financial position, results of operations, cash flows, or disclosures.

INVENTORIES (Tables)

9 Months Ended

Sep. 30, 2023

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories consisted of the following (in thousands):


	September 30, 2023		December 31, 2022

Raw materials	$	8,491	$	12,670
Packaging	2,269		3,611
Non-food finished goods	4,426		8,738
Finished goods	49,558		97,675
Reserve for obsolete inventory	(6,517)		(3,838)
Total	$	58,227	$	118,856

EARNINGS PER SHARE (Tables)

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

Schedule of the Computation of Basic and Diluted EPS

The following table sets forth the computation of basic and diluted EPS (in thousands, except per share data):


	Three months ended September 30,				Nine months ended September 30,
	2023		2022		2023		2022

Numerator:
Net income	$	23,131	$	36,155	$	93,380	$	117,050

Denominator:
Weighted average shares of common stock outstanding	10,892		10,964		10,881		11,290
Effect of dilutive common stock equivalents	41		78		44		79
Weighted average shares of common stock outstanding	10,933		11,042		10,925		11,369

Earnings per share - basic	$	2.12	$	3.30	$	8.58	$	10.37

Earnings per share - diluted	$	2.12	$	3.27	$	8.55	$	10.30

SHARE-BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2023

Share-Based Payment Arrangement [Abstract]

Schedule of Stock Option Activity

The following table is a summary of our stock option activity (in thousands, except per share data):


	Nine months ended September 30,
	2023			2022
	Awards	Weighted-Average Exercise Price		Awards	Weighted-Average Exercise Price

Outstanding at beginning of period	33	$	54.98	33	$	54.98
Exercised	(4)	27.18		—	—
Outstanding at end of the period	29	$	58.65	33	$	54.98
Exercisable at end of the period	29	$	58.65	28	$	52.76

Schedule of Restricted Stock Activity

The following table summarizes our restricted stock activity (in thousands, except per share data):


	Nine months ended September 30,
	2023			2022
	Shares	Weighted-Average Grant Date Fair Value		Shares	Weighted-Average Grant Date Fair Value

Outstanding at beginning of period	60	$	188.11	44	$	183.51
Granted	86	97.96		38	176.60
Vested	(25)	169.46		(19)	156.16
Forfeited	(5)	142.11		(1)	186.53
Outstanding at end of the period	116	$	127.57	62	$	187.83

Schedule of Share-based Compensation Expense

The total expense during the three months ended September 30, 2023 and 2022 as follows (in thousands):


	Three months ended September 30,
	2023			2022
	Shares	Share-Based Compensation Expense		Shares	Share-Based Compensation Expense
Options and restricted stock	145	$	1,558	90	$	1,392
Market and performance-based share awards granted in 2023	47	487		—	—
Market and performance-based share awards granted in 2022	24	—		25	438
Performance-based share awards granted in 2021	14	620		15	654
Performance-based share awards granted in 2020	28	10		26	479
Total share-based compensation	258	$	2,675	156	$	2,963

The total expense during the nine months ended September 30, 2023 and 2022 as follows (in thousands):


	Nine months ended September 30,
	2023			2022
	Shares	Share-Based Compensation Expense		Shares	Share-Based Compensation Expense
Options and restricted stock	145	$	4,426	90	$	3,789
Market and performance-based share awards granted in 2023	47	1,048		—	—
Market and performance-based share awards granted in 2022	24	(1,388)		25	950
Performance-based share awards granted in 2021	14	1,600		15	1,941
Performance-based share awards granted in 2020	28	109		26	1,423
Total share-based compensation	258	$	5,795	156	$	8,103

LEASES (Tables)

9 Months Ended

Sep. 30, 2023

Leases [Abstract]

Schedule of Supplemental Cash Flow Information

Supplemental cash flow information related to the Company’s operating leases was as follows (in thousands):


	Nine months ended September 30,
	2023		2022

Cash paid for amounts included in the measurements of lease liabilities
Operating cash flow used in operating leases	$	4,838	$	5,413

Right-of-use assets obtained in exchange for lease obligations
Operating leases	$	753	$	103

Schedule of Maturity of Company's Operating Lease Liabilities

The following table presents the maturity of the Company’s operating lease liabilities as of September 30, 2023 (in thousands):


2023 (excluding the nine months ended September 30, 2023)	$	1,435
2024	5,955
2025	6,095
2026	4,438
2027	2,553
Thereafter	2,858
Total lease payments	$	23,334
Less: imputed interest	(990)
Total	$	22,344

ACCUMULATED OTHER COMPREHENSIVE INCOME (Tables)

9 Months Ended

Sep. 30, 2023

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]

Schedule of Accumulated Other Comprehensive Income

The following table sets forth the components of accumulated other comprehensive income, net of tax where applicable (in thousands):


	September 30, 2023		December 31, 2022

Foreign currency translation	$	150	$	24
Unrealized net losses on investment securities	(9)		—
Accumulated other comprehensive (loss)/income	$	141	$	24

FINANCIAL INSTRUMENTS (Tables)

9 Months Ended

Sep. 30, 2023

Investments, All Other Investments [Abstract]

Schedule of Cash and Financial Assets Measured at Fair Value on a Recurring Basis

The following tables present the Company’s cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands):


	September 30, 2023
	Cost		Unrealized Gains (Losses)		Accrued Interest		Estimated Fair Value		Cash & Cash Equivalents		Investment Securities

Cash	$	107,656	$	—	$	—	$	107,656	$	107,656	$	—

Level 1:
Money market accounts	5,033		—		62		5,095		5,095		—
Government & agency securities	15,200		17		28		15,245		—		15,245

	20,233		17		90		20,340		5,095		15,245

Level 2:
Corporate bonds	29,579		(26)		211		29,764		—		29,764

Total	$	157,468	$	(9)	$	301	$	157,760	$	112,751	$	45,009


	December 31, 2022
	Cost		Unrealized Gains (Losses)		Accrued Interest		Estimated Fair Value		Cash & Cash Equivalents		Investment Securities

Cash	$	87,691	$	—	$	—	$	87,691	$	87,691	$	—

Level 1:
Money market accounts	—		—		—		—		—		—
Government & agency securities	—		—		—		—		—		—
	—		—		—		—		—		—




Total	$	87,691	$	—	$	—	$	87,691	$	87,691	$	—

INVENTORIES (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 8,491	$ 12,670
Packaging	2,269	3,611
Non-food finished goods	4,426	8,738
Finished goods	49,558	97,675
Reserve for obsolete inventory	(6,517)	(3,838)
Total	$ 58,227	$ 118,856

EARNINGS PER SHARE - Computation of Basic and Diluted EPS (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2023	Sep. 30, 2022
Numerator:
Net income	$ 23,131	$ 30,280	$ 39,968	$ 36,155	$ 39,113	$ 41,781	$ 93,380	$ 117,050
Denominator:
Weighted average shares of common stock outstanding (in shares)	10,892			10,964			10,881	11,290
Effect of dilutive common stock equivalents (in shares)	41			78			44	79
Weighted average shares of common stock outstanding (in shares)	10,933			11,042			10,925	11,369
Earnings per share - basic (in usd per share)	$ 2.12			$ 3.30			$ 8.58	$ 10.37
Earnings per share - diluted (in usd per share)	$ 2.12			$ 3.27			$ 8.55	$ 10.30

EARNINGS PER SHARE - Narrative (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Restricted Stock
Anti-dilutive awards (in shares)	13	10	15	3

SHARE-BASED COMPENSATION - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation, shares authorized under stock option plans, exercise price range, lower range limit (in usd per share)			$ 26.52
Share-based compensation, shares authorized under stock option plans, exercise price range, upper range limit (in usd per share)			$ 66.68
Awards granted (in shares)			0	0
Weighted-average remaining contractual life of options outstanding (in years)			3 years 9 months 18 days
Weighted-average remaining contractual life of options exercisable (in years)			3 years 9 months 18 days
Aggregate intrinsic value of options outstanding	$ 500		$ 500
Aggregate intrinsic value of options exercisable	500		500
Proceeds from stock options exercised			100
Intrinsic value of options exercised			300
Decrease in share-based payment arrangement, expense	(2,675)	$ (2,963)	(5,795)	$ (8,103)
Total income tax benefit recognized related to restricted stock awards	300	400	$ 400	$ 1,200
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			3 years
Award expiration period (in years)			10 years
Compensation expense			$ 100
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)			5 years
Shares withheld for employee taxes			10,000	8,000
Share-based compensation arrangement, fair value of awards vested			$ 2,600	$ 3,400
Unrecognized compensation costs	9,300		$ 9,300
Compensation cost recognition weighted average period (in years)			1 year 10 months 24 days
Shares granted in period			86,000	38,000
Shares vested in period			25,000	19,000
Performance-based Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance period (in years)			3 years
Performance-based Shares \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares earned (as a percent)			0.00%
Performance-based Shares \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares earned (as a percent)			250.00%
Market and Performance-based Share Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares withheld for employee taxes			22,000	0
Share-based compensation arrangement, fair value of awards vested			$ 5,700	$ 0
Unrecognized compensation costs	5,100		$ 5,100
Compensation cost recognition weighted average period (in years)			1 year 9 months 18 days
Shares granted in period			113,000
Shares vested in period				0
Market and Performance-based Share Awards \| Granted In 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Decrease in share-based payment arrangement, expense	$ 0	$ (438)	$ 1,388	$ (950)

SHARE-BASED COMPENSATION - Stock Options Activity (Details) - $ / shares shares in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Awards
Outstanding at beginning of period (in shares)	33	33
Exercised (in shares)	(4)	0
Outstanding at end of the period (in shares)	29	33
Exercisable at end of the period (in shares)	29	28
Weighted-Average Exercise Price
Outstanding at beginning of period (in usd per share)	$ 54.98	$ 54.98
Exercised (in usd per share)	27.18	0
Outstanding at beginning of period (in usd per share)	58.65	54.98
Exercisable at end of the period (in usd per share)	$ 58.65	$ 52.76

SHARE-BASED COMPENSATION - Restricted Stock Activity (Details) - Restricted Stock - $ / shares shares in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Shares
Outstanding at beginning of period (in shares)	60	44
Granted (in shares)	86	38
Vested (in shares)	(25)	(19)
Forfeited (in shares)	(5)	(1)
Outstanding at end of period (in shares)	116	62
Weighted-Average Grant Date Fair Value
Outstanding at beginning of period (in usd per share)	$ 188.11	$ 183.51
Granted (in usd per share)	97.96	176.60
Vested (in usds per share)	169.46	156.16
Forfeited (in usd per share)	142.11	186.53
Outstanding at beginning of period (in usd per share)	$ 127.57	$ 187.83

SHARE-BASED COMPENSATION - Summary of Performance-based Share Awards (Details) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares	258	156	258	156
Share-Based Compensation Expense	$ 2,675	$ 2,963	$ 5,795	$ 8,103
Options and restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares	145	90	145	90
Share-Based Compensation Expense	$ 1,558	$ 1,392	$ 4,426	$ 3,789
Market and performance-based share awards \| Granted In 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares	47	0	47	0
Share-Based Compensation Expense	$ 487	$ 0	$ 1,048	$ 0
Market and performance-based share awards \| Granted In 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares	24	25	24	25
Share-Based Compensation Expense	$ 0	$ 438	$ (1,388)	$ 950
Performance-based share awards \| Granted In 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares	14	15	14	15
Share-Based Compensation Expense	$ 620	$ 654	$ 1,600	$ 1,941
Performance-based share awards \| Granted In 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares	28	26	28	26
Share-Based Compensation Expense	$ 10	$ 479	$ 109	$ 1,423

LEASES - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
LEASES - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Lessee, Lease, Description [Line Items]
Operating lease expense	$ 1.1	$ 1.7	$ 3.9	$ 5.2
Weighted average remaining lease term	4 years 2 months		4 years 2 months
Weighted average discount rate (as a percent)	2.00%		2.00%
Minimum \| Operating Lease Arrangement for Real Estate
Lessee, Lease, Description [Line Items]
Lease term (in months)	19 months		19 months
Minimum \| Operating Lease Arrangement for Equipment
Lessee, Lease, Description [Line Items]
Lease term (in months)	24 months		24 months
Maximum \| Operating Lease Arrangement for Real Estate
Lessee, Lease, Description [Line Items]
Lease term (in months)	122 months		122 months
Maximum \| Operating Lease Arrangement for Equipment
Lessee, Lease, Description [Line Items]
Lease term (in months)	203 months		203 months

LEASES - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Leases [Abstract]
Operating cash flow used in operating leases	$ 4,838	$ 5,413
Right-of-use assets obtained in exchange for lease obligations	$ 753	$ 103

LEASES - Future Minimum Lease Commitments (Details) $ in Thousands	Sep. 30, 2023 USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2023 (excluding the nine months ended September 30, 2023)	$ 1,435
2024	5,955
2025	6,095
2026	4,438
2027	2,553
Thereafter	2,858
Total lease payments	23,334
Less: imputed interest	(990)
Total	$ 22,344

ACCUMULATED OTHER COMPREHENSIVE INCOME (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Foreign currency translation	$ 150	$ 24
Unrealized net losses on investment securities	(9)	0
Accumulated other comprehensive (loss)/income	$ 141	$ 24

FINANCIAL INSTRUMENTS - Cash and Financial Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Cash And Cash Equivalents And Marketable securities [Line Items]
Cost, Cash and Cash Equivalents	$ 112,751	$ 87,691
Cost, Total	157,468	87,691
Unrealized Gains (Losses)	(9)	0
Accrued Interest	301	0
Estimated Fair Value, Cash and cash equivalents	112,751
Investment securities	45,009	0
Estimated Fair Value, Total	157,760	87,691
Cash
Cash And Cash Equivalents And Marketable securities [Line Items]
Cost, Cash and Cash Equivalents	107,656	87,691
Estimated Fair Value, Cash and cash equivalents	107,656	87,691
Level 1 \| Money market accounts and government & agency securities
Cash And Cash Equivalents And Marketable securities [Line Items]
Cost, Total	20,233	0
Unrealized Gains (Losses)	17	0
Accrued Interest	90	0
Investment securities	15,245	0
Estimated Fair Value, Total	20,340	0
Level 1 \| Money market accounts
Cash And Cash Equivalents And Marketable securities [Line Items]
Cost, Cash and Cash Equivalents	5,033	0
Accrued Interest	62	0
Estimated Fair Value, Cash and cash equivalents	5,095	0
Level 1 \| Government & agency securities
Cash And Cash Equivalents And Marketable securities [Line Items]
Cost, Investment Securities	15,200	0
Unrealized Gains (Losses)	17	0
Accrued Interest	28	0
Investment securities	15,245	$ 0
Level 2 \| Corporate bonds
Cash And Cash Equivalents And Marketable securities [Line Items]
Cost, Investment Securities	29,579
Unrealized Gains (Losses)	(26)
Accrued Interest	211
Investment securities	$ 29,764

FINANCIAL INSTRUMENTS - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Investments, All Other Investments [Abstract]
Realized gain or loss	$ 0	$ 0	$ 0	$ 0

DEBT (Details) - Credit Agreement		9 Months Ended
DEBT (Details) - Credit Agreement	Apr. 13, 2021 USD ($)	Sep. 30, 2023 USD ($)	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Maximum total net leverage ratio	2.75
Minimum interest coverage ratio	3.50
Outstanding borrowings		$ 0	$ 0
SOFR
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		1.25%
Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate (as a percent)		0.25%
Minimum
Debt Instrument [Line Items]
Commitment fee (as a percent)	0.20%
Maximum
Debt Instrument [Line Items]
Commitment fee (as a percent)	0.40%
Revolving Credit Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 225,000,000
Letter of Credit
Debt Instrument [Line Items]
Maximum borrowing capacity	20,000,000
Uncommitted Incremental Facility
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 100,000,000

ACCELERATED SHARE REPURCHASE ("ASR") PROGRAM (Details) - USD ($) shares in Thousands	Aug. 08, 2022	May 31, 2022	Jun. 30, 2022
Equity [Abstract]
Repurchase amount			$ 100,000,000
Initial amount received (in shares)	91	480

Medifast (NYSE:MED)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025

Medifast (NYSE:MED)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

MED Medifast Inc

Medifast Inc News

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

MED Medifast Inc

Medifast Inc News

최근 히스토리

회사 소개

사업

Popular

앱 받기

광고 제거